Provention Bio to Present at the SVB Securities Global Biopharma Conference
Provention Bio, Inc. (Nasdaq: PRVB) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Provention Bio, Inc. (Nasdaq: PRVB) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM EST. The event will be webcast live, accessible through the company's website, and archived for 30 days. Provention focuses on developing therapies for immune-mediated diseases, with a pipeline targeting conditions like Type 1 Diabetes, celiac disease, and lupus. For additional information, visit www.ProventionBio.com.
Details
News Market Reaction – PRVB
The recorded move for PRVB in the trading session of this news was -2.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15th, 2023 at 11:20am EST.
The presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company's website: http://investors.proventionbio.com/events. The webcast will be archived on the Company's website for 30 days following the presentation.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a commercial-stage biopharmaceutical company focused on advancing the development and commercialization of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contact:
Kristen Kelleher, Senior Manager, Investor Relations
investorrelations@proventionbio.com
Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-svb-securities-global-biopharma-conference-301740966.html
SOURCE Provention Bio, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.